A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer

Trial Profile

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Guadecitabine (Primary)
  • Indications Gastrointestinal stromal tumours; Paraganglioma; Pheochromocytoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 12 Aug 2017 Planned initiation date changed from 16 Aug 2017 to 18 Aug 2017.
    • 10 Aug 2017 Planned initiation date changed from 14 Aug 2017 to 15 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top